NBS stock price is on the rise again after NeoStem Inc. (NYSE MKT: NBS) was upgraded by analysts at WBB Securities from a “buy” to a “strong-buy“. The stem cell stock appears to be closing in on its 9th positive trading session ot of the ...
February was a tough month for biotech stocks researching stem cells for the treatment and cure of diseases. TickerSpy’s Stem Cell Stocks Index (RXSTM) has slipped nearly 13% since early February being outperformed by the S&P 500 by close to 17% during that time.
Four particular stem cell stocks, all cheap stocks under 5 including 2 penny stocks, should ...
Continue Reading →
Amorcyte, LLC, a NeoStem, Inc. company (AMEX: NBS) announced the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction. The study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of infarct-related artery infusion of AMR-001, an autologous ...
“Be fearful when others are greedy, and be greedy when others are fearful.” – Warren Buffett
NeoStem, Inc.(AMEX:NBS) announced today that its Chief Medical Officer, the lead investigator for its PreSERVE Phase 2 clinical trial for AMR-001 for preservation of heart function in post ...
Continue Reading →
When screening for the best penny stock to buy now, profitability, liquidity and risk tolerance all come in to play which is why NeoStem Inc. (AMEX NPS) makes for an interesting investment. A penny stock like this provides exposure to the world of cutting edge stem cell therapeutics and allure of developing markets- at ...
Continue Reading →